Kornimate/medical-research-clean huggingface dataset:
weight-bearing of patients after pelvic ring fracture

Conditions: Weight-bearing of Patients After Pelvic Ring Fracture

Summary: pelvic ring fractures are fractures associated with high morbidity and mortality. when the fracture is displaced, surgical management to achieve reduction and fixation of the anterior and posterior annulus is the current reference. the optimal technique that gives the best results is controversial. open reductions and internal fixations (orifs) are associated with more blood loss and a higher rate of infection, while closed reductions and percutaneous fixations (crpf) are associated with more screw misplacements and thus vascular or nerve damage. the results appear to be similar in the literature between the two approaches surgery for pelvic ring fractures has become increasingly common over the past three decades recovery is often delayed for weeks post-surgery, depending on the center. modern management emphasizes early rehabilitation, including early mobility and weight-bearing, when possible. increasing the number of screws, their diameter and length, and systematically fixing both anterior and posterior lesions add safety for early reloading the aim of the study is the main objective of the study is to evaluate the clinical outcome associated with early weight-bearing in patients operated on for a pelvic ring fracture in a large cohort of patients at grenoble university hospital, compared to patients operated on for the same type of pelvic ring fracture with delayed weight-bearing. the investigator hypothesize that early weight-bearing of pelvic ring fractures with biomechanically stable fixation does not result in significant differences in clinical outcomes at a minimum of one year compared to patients with delayed weight-bearing


Eligibility criteria:
inclusion criteria: * adult patient at the time of injury * pelvic ring fracture * pre-operative x-rays * pre-operative ct scan * post-operative x-rays * postoperative ct scan * willingness and ability to participate in the study. exclusion criteria: * ipsi-lateral fracture of the femoral and/or associated acetabulum (floating hip c or b) * pregnant and breastfeeding women * people under guardianship, protected adults
continuous glucose monitoring in adolescents with poorly controlled type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to see if children and adolescents with poorly controlled type 1 diabetes will benefit from using a continuous glucose monitor (cgm), a device that can be used to check blood sugars.

adolescents with type 1 diabetes, hba1c ≥9% on insulin pumps were admitted to the clinical research center and a continuous glucose sensor was inserted. sensor glucose (sg) values were compared to plasma glucose measured at least hourly using yellow springs instrument's (ysi) glucose analyzer. sg rather than ysi was used for treatment decisions unless ysi was \<70 mg/dl or specific criteria indicating sg and ysi were very discordant were met.

Eligibility criteria:
inclusion criteria: * 12 to \<18 years old * t1d for at least one year * treatment with insulin pump therapy * a1c ≥9% * willingness to comply with study procedures exclusion criteria: * current diabetic ketoacidosis * hypoglycemia unawareness * chronic use of medications that affect recognition of hypoglycemia (e.g., beta blockers) * chronic use of medications that mimic symptoms of high or low blood sugars (e.g., decongestants) * recent or frequent severe hypoglycemia (2 episodes in the last year; 1 episode in the last 6 months) * skin rashes or conditions that may affect cgm placement and wear

Keywords: type 1 diabetes adolescents poor control cgm
the effect of appropriate family companionship on the physical and mental health of patients with advanced breast cancer

Conditions: Breast Cancer

Summary: the goal of this clinical trial is to learn about companionship needs in breast cancer patients who are pathologically or cytologically diagnosed as cancer, are alive with the tumor, and have tnm clinical stage iv. the main questions it aims to answer are: 1. patients with advanced breast cancer need family companionship 2. analyze and study the reasons and factors that affect the physical and mental impact of effective family companionship on patients with advanced breast cancer participants will be divided into a companion group and a non-accompaniment group. patients in the companion group are given graded companion intervention methods. a comparison group: researchers will compare a non-accompaniment group to see if the physical and mental impact of companionship on patients.


Eligibility criteria:
inclusion criteria: * breast cancer patients who are pathologically or cytologically diagnosed as cancer * tnm clinical stage iv exclusion criteria: * terminal cancer patients who are mentally ill or confused and refuse to participate in the survey
condylar segment repositioning using cad/cam generated wafer after bsso in skeletal mandibular deformity

Conditions: Skeletal Abnormalities

Summary: maintaining the condylar position after bilateral sagittal split ramus osteotomy (bsso) is one of the most important aspects in terms of condylar function ,.an altered condylar position can cause internal derangement of the joint, loss of the mandibular angle, increased risk of relapse, condyle sagging, and impaired masticatory function. in previous years, a great deal of attention has been paid to maintaining the preoperative condylar position during orthognathic surgery. numerous condylar positioning methods have been reported and could be divided into manual/empirical methods, conventional methods , navigation, and sonographic monitoring, computer guided methods which is more accurate than other methods

unpredictable condylar position after orthognathic surgery, will lead to malocclusion, derangement of the condylar surface, condylar resorption, condylar sag, distraction of the condyles from the fosse. in previous years, several authors had been adopted several techniques to maintain the preoperative condylar position during orthognathic surgery. numerous condylar positioning methods have been reported which could be divided into conventional techniques (manual maneuvers or aiding tools), extra and intra oral navigational techniques , surgeons had been utilized these techniques in condylar repositiong after bsso but it was time and effort consuming and sometimes it was inaccurate. the aim for conducting the research is accurate positioning of condyle three dimensionally to minimize effort and operating time of surgery .

Eligibility criteria:
inclusion criteria: * age of the patient above 18 years * patients needs bilateral sagittal split osteotomy * all patients are free from any systemic disease that may affect normal bone healing * sufficient dentition to reproduce the occlusal relationships * patient's consent to participate exclusion criteria: * patient with tmj disorders * patients with any systemic disease that may affect normal healing * intra-bony lesions or infections that may interfere with surgery.the presence of * previous orthognathic surgeries
special investigation for patients with renal and/or hepatic disorders on aromasin

Conditions: Breast Neoplasms

Summary: the objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the lpd (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

all the patients whom an investigator prescribes the first exemestane (aromasin) should be registered.

Eligibility criteria:
inclusion criteria: * subjects with postmenopausal breast cancer (including ovariectomy etc.). exclusion criteria: * patients cannot be evaluated.for example, not administered exemestane (aromasin).
valeo: a post authorization study, designed to learn more about the safety and effectiveness of the use of bortezomib in the netherlands

Conditions: Multiple Myeloma; Hematological Neoplasms

Summary: the main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the netherlands.

bortezomib has become commercially available in the european union in may 2004 for the third line treatment of patients with multiple myeloma. the registration was based on two phase ii studies while more research was ongoing. some experience was already gained with the use of this product in the netherlands by means of a compassionate use program before the initial registration. however, the data available from the use of bortezomib in daily clinical practice is limited. therefore, there is a need to closely study the use of bortezomib in daily clinical practice. during the course of the study, the registration of bortezomib was extended. in april 2005, bortezomib was registered for second line treatment of multiple myeloma. consequently, safety and effectiveness data from patients in this line of treatment could be collected in this project as well (arm a). data of a large phase 3 trial showed that response rates differ between patients treated for multiple myeloma in the second line and patients treated in the third line. therefore the protocol was amended to compare the response rates in two arms, dependent on the number of previous treatment lines for multiple myeloma: the protocol was also amended to determine the time to progression and response rate in both patients who received thalidomide earlier versus patients who didn't (arm b). arm a: patients with relapsed multiple myeloma who have received not more than 1 previous line of treatment and show progression on that therapy; arm b: patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of treatment and show progression on most recent therapy. this project is a 'post authorization study (pas)'. this means that only routinely available medical data is collected, with the patients' permission, and no additional interventions or diagnostic procedures should be done specifically for this study. because the study is observational, dosage, administration and duration of treatment is at discretion of treating physician.

Eligibility criteria:
inclusion criteria: * patients have to sign a statement that they agree with collection of their clinical data for this project * the patient is eligible, in the investigator's opinion, based on the criteria in the summary of product characteristics for bortezomib exclusion criteria: * if patients meet the eligibility criteria, there are no exclusion criteria.

Keywords: multiple myeloma hematological neoplasms chemotherapy efficacy safety bortezomib proteasome inhibitor
telemedicine clinic for prostate cancer patients

Conditions: Cancer, Treatment-Related

Summary: this randomized, open label study will evaluate a nurse and pharmacist led clinic conducted remotely from grand river regional cancer centre at grand river hospital (grrcc/grh) using otn teleconferencing as a platform for patients with prostate cancer receiving oral chemotherapy agents.


Eligibility criteria:
inclusion criteria: 1. male over 18 years of age with prostate cancer receiving oral treatment with abiraterone or enzalutamide. 2. ability to provide consent to study. 3. willingness to complete study questionnaires and a semi-structured exit interview. 4. adequate command of the english language to complete study questionnaire and survey. 5. access to technology to allow a link to the virtual telemedicine clinic. (excluding control group) 6. willingness to participate in videoconference with pharmacist or nurse from their home environment. (excluding control group) exclusion criteria: 1. patients receiving oral anti-cancer therapy other than abiraterone and enzalutamide. 2. patients lacking the technology at home to participate in the virtual telemedicine clinic. (excluding control group) -
immunogenicity, safety and tolerability of prepandemic influenza and seasonal influenza vaccine in adult subjects

Conditions: Pandemic; Avian Influenza

Summary: this study evaluates the immunogenicity, safety and tolerability of an h5n1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by who for the 2007 influenza season in the southern hemisphere.


Eligibility criteria:
inclusion criteria: * healthy subjects

Keywords: bird flu influenza vaccine seasonal influenza vaccine prepandemic vaccine
a randomized study of early palliative care

Conditions: Quality of Life

Summary: the purpose of this research study is to find out whether it is better to introduce cancer patients to the palliative care team at a later date when there is a specific issue or problem or to introduce cancer patients to the palliative care team when first diagnosed before any specific issue or problem occurs.

the investigators will conduct a one-year randomized, controlled study to evaluate the impact of an early, integrated palliative care services. the intervention will include comprehensive palliative care services delivered in conjunction with standard oncology care and patient friendly materials for high risk oncology patients. the investigators primary clinical endpoint will be health related quality of life, specifically focusing on measures of anxiety, depression, and well-being. secondary personalized palliative care outcomes are expected to include: * reduced deviations from care plan as captured in the medical record compared to the group who did not receive early, integrated palliative care services * reduced hospital utilization compared to the group who did not receive early, integrated palliative care services

Eligibility criteria:
inclusion criteria: * -adults with newly diagnosed pancreatic, hepatocellular, esophageal, or stomach cancer * upcoming scheduled oncology clinic visit (2nd visit to the clinic) at vanderbilt * ability to read and respond to questions in english * permission of oncology physician exclusion criteria: * -receiving oncology care at non-vanderbilt sites (to ensure appropriate follow-up) * participation in another clinical trial

Keywords: palliative care
magnesium and vanadium levels in preeclampsia

Conditions: Preeclampsia

Summary: introduction: vanadium important pollutants produced from anthropogenic activities, has been suggested to be embryotoxic and fetotoxic in a lot of studies. magnesium sulfate therapy is used very common to prevent seizures in women with preeclampsia. however, the causes of preeclampsia are little known and heavy metals merit further investigation. the investigators will be tested whether late - onset preeclampsia (lope) was associated with exposure to these metals. methods: this study was designed to determine maternal plasma/urine/hair magnesium and vanadium concentrations in women with lope (n=70) compared to those of normotensive pregnant women (n=70) and to those of normotensive-healthy non-pregnant women (n=70). these metals concentrations will be measured using inductively coupled plasma-mass spectrometry were compared.

this observational case-control study will be conducted at the department of obstetrics and gynecology, cengiz gokcek public hospital, gaziantep, turkey, between may 2020 and february 2021. the protocol was approved by the ethics committee for clinical research of gaziantep university (reference no: 2020/130). the study strictly will be adhered to the principles of the declaration of helsinki. all participants will be included in the study gave oral and written informed consent. two-hundred ten women will be enrolled in the study in three groups.

Eligibility criteria:
inclusion criteria: * preeclampsia * healthy pregnancy * healthy women exclusion criteria: 1. pregnant women with any systemic condition (such as chronic hypertension, renal disease and diabetes mellitus) 2. using any kind of medication/supplement intake throughout pregnancy (such as heparin) 3. history of medication for pe treatment at the time of first admission 4. smoking 5. drug user 6. patients who had fetal congenital abnormalities or genetic syndromes 7. multiple-gestation pregnancies 8. pregnancies resulting from in vitro fertilization 9. intrauterine fetal death 10. having a family history of preeclampsia 11. women who have menstrual irregularity 12. women who have dyed their hair in the last 9 months 13. gestational diabetes mellitus 14. women receiving vanadium and/or magnesium treatment
inmediate feeding tolerance in acute pancreatitis

Conditions: Acute Pancreatitis Due to Gallstones

Summary: objective: determine tolerance of immediate oral intake (8 hours posterior to the beginning of treatment) against traditional management (early feeding at 48hr) in patients with mild acute pancreatitis of biliary origin. double blind, randomized clinical trial

the investigators included patients 15 - 85 years old, any sex. diagnosis of mild acute pancreatitis according to the ranson, apache ii and bisap. signed infromed consent to participate in the study. all participants had a hepatic and biliary ultrasound to determine the biliary etiology. the investigators excluded patients with pancreatitis of nonbiliary etiology, pregnant, severe pancreatitis, cholangitis or choledocholithiasis demonstrated during the hospital stay or with other comorbidities.

Eligibility criteria:
inclusion criteria: patients older than 15 years. * patients with a diagnosis of mild acute pancreatitis biliary. * patients who agree to enter the protocol. exclusion criteria: * patients managed at another institution. * patients with a diagnosis of pancreatitis of non-biliary etiology. * patients with heart disease or lung disease. * patients with organic failure. * patients with pregnancy. * patients with cholangitis.

Keywords: pancreatitis mild biliary referring
effect of ranolazine on valvular disease in patients with pacemakers

Conditions: Ischemic Mitral Regurgitation

Summary: the purpose of this study is to find out whether mitral regurgitation (or a leaky heart valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve after administration of ranolazine.


Eligibility criteria:
inclusion criteria: * ischemic cardiomyopathy and * moderate or severe mitral regurgitation and * cardiac resynchronization therapy (crt) ≥ 3 months prior to enrollment and * maximal medical therapy (ace-inhibitor, beta blocker, aldosterone antagonist, diuretic, aspirin, statin) exclusion criteria: * nonischemic cardiomyopathy * active heart failure * current ranolazine therapy * congenital heart disease * mechanical valve prostheses * vegetation/endocarditis * significant pulmonary disease * peripheral vascular disease * trivial or mild mitral regurgitation * creatinine clearance \< 30 ml/min * liver cirrhosis * strong inhibitors of cyp3a (including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir) * strong inducers of cyp3a (including rifampin, rifapentine, phenobarbital, phenytoin, carbamazepine and st.john's wort) * strong p-glycoprotein inhibitors (including cyclosporine, verapamil, and quinidine) * initial qtc interval ≥ 440msec

Keywords: mitral regurgitation cardiac resynchronization therapy ranolazine maximal medical therapy ischemic cardiomyopathy
surgical resection outcomes in patients with brain metastasis

Conditions: Brain Metastases

Summary: while many studies have investigated the prognostic factors for patients undergoing surgical resection for primary brain tumors, decision-making for patients with brain metastasis (bm) is more complex because of their higher burden of comorbidities compared to those with primary brain tumors. in addition, although various prognostic indicators have been identified to predict prognosis in several types of cancer, such as the neutrophil-to-lymphocyte ratio (nlr), platelet-to-lymphocyte ratio (plr), prognostic nutritional index (pni), and systemic immune-inflammation index (sii), limited studies have yet determined which group of patients would yield beater survival outcome after surgical resection for bm. this study aimed to investigate the impact of patient and perioperative characteristics and prognostic indicators on survival outcome of patients undergoing surgical resection of bm.


Eligibility criteria:
inclusion criteria: 1. patients with clinical diagnosis of brain metastasis 2. patients who underwent craniotomy surgery for brain metastasis exclusion criteria: 1. patients with insufficient data for associated factors 2. patients who underwent stereotactic biopsy for brain metastasis 3. patients who did not undergo craniotomy surgery for brain metastasis
efficacy of gonb in patients of migraine

Conditions: Chronic Migraine; Headache

Summary: the study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. it was a randomised controlled which took place from april 2022 - october 2022. fifty patients suffering from migraine were included in the study. patients in group g were given greater occipital nerve block (gonb) with lignocaine and dexamethasone under ultrasound guidance while those in group s were given saline 0.9% as placebo. pain score using numeric rating scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. total headache days were recorded as a secondary outcome.


Eligibility criteria:
inclusion criteria: * patients between 18 to 60 years * diagnosed case of migraine exclusion criteria: * patients with known allergies to local anaesthetics * pregnancy * history of cranial or cervical surgery * head injury * headaches secondary to medication overuse * patients with uncontrolled systemic disease like blood pressure, diabetes mellitus * hypo or hyperthyroidism * patient who had already received gonb or botulinum toxin type a therapy within last 6 months * major psychiatric disorder * history of chronic pain syndromes
effect of multiple repeat cesarean sections on intra-abdominal adhesions

Conditions: Cesarean Section Complications

Summary: the rate of cesarean section deliveries has increased dramatically worldwide in the last decades. while the cesarean birth rate was 4.5% in the usa in 1965, it was 31.8% according to 2007 data and is thought to be over 50% at present. the reasons for this include advanced age of primigravida, a wide range of indications, patient requests, the frequency of women with previous cesareans, women's rejections to offers of sterilization, and the common usage of assisted reproductive techniques


Eligibility criteria:
inclusion criteria: 1. women with at least previous one cesarean section. 2. women accepted to participate in the study. exclusion criteria: 1. previous abdominopelvic surgery other than cesarean section. 2. history of pelvic inflammatory disease. 3. women refuse to participate in the study. 4. intrauterine fetal death